While the NF-κB pathway has already been described as being associated with trabectedin resistance in myxoid liposarcoma [26], we decided to explore the inhibition of the mTOR pathway in combination with trabectedin, since to our knowledge, specific HMGA1 inhibitors are not currently available for research. The gene discussed is MTOR; the disease is myxoid liposarcoma.